Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Avipendekin Pegol · NKTR-255

Fusion protein · Immune activation, directed at IL-15 receptor alpha (IL15RA) · developed by Nektar Therapeutics

Phase 2 Most advanced trial

1 Registered trials

What is Avipendekin Pegol?

Avipendekin pegol is a long-acting IL-15 conjugated with polymers that binds IL-15 receptor alpha on NK and T cells, activating their expansion and anti-tumor responses. It is studied in locally advanced or metastatic urothelial carcinoma and may enhance antibody-dependent cell-mediated cytotoxicity when combined with tumor-directed antibodies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: NKTR-255
Drug type: Fusion protein
Targets: IL-15 receptor alpha (IL15RA)
Mechanism: Immune activation, directed at IL-15 receptor alpha (IL15RA)
Pathways: NK cell activation, CD8+ T cell expansion, antibody-dependent cell-mediated cytotoxicity
Therapy area: Oncology
Developer: Nektar Therapeutics
In trials of: GILD, MRK
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: K25K2Y6N8C

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05327530	Phase 2	Locally Advanced or Metastatic Urothelial Carcinoma	Active not recruiting	GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Locally Advanced or Metastatic Urothelial Carcinoma

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z